Gordian Capital Singapore Pte Ltd Makes New Investment in Tempus AI, Inc. $TEM

Key Points

• Gordian Capital Singapore Pte Ltd acquired 5,000 shares of Tempus AI, Inc., valued at approximately $241,000, marking a new position for the firm in the first quarter.
• Tempus AI, Inc. reported quarterly earnings of ($0.22) EPS, slightly exceeding analysts' estimates, with revenue increasing by 89.5% year-over-year to $314.64 million.
• Several hedge funds, including ARK Investment Management LLC and Vanguard Group Inc., significantly increased their holdings in Tempus AI, indicating strong institutional interest in the company.

Gordian Capital Singapore Pte Ltd bought a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,000 shares of the company's stock, valued at approximately $241,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock worth $289,204,000 after buying an additional 5,900,668 shares during the period. ARK Investment Management LLC boosted its position in shares of Tempus AI by 35.9% during the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock worth $361,867,000 after buying an additional 1,981,755 shares during the period. Nikko Asset Management Americas Inc. boosted its position in shares of Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock worth $205,401,000 after buying an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after buying an additional 1,016,384 shares during the period. Finally, CloudAlpha Capital Management Limited Hong Kong acquired a new position in shares of Tempus AI during the first quarter worth approximately $34,119,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a research report on Friday, August 8th. Bank of America upped their price target on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Guggenheim upped their price target on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a report on Monday, June 30th. BTIG Research upped their price target on Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, August 20th. Finally, Morgan Stanley upped their price target on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $67.64.

Insider Transactions at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of the company's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $74.10, for a total value of $24,638,250.00. Following the completion of the sale, the chief executive officer directly owned 9,207,533 shares in the company, valued at approximately $682,278,195.30. This represents a 3.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James William Rogers sold 7,528 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the sale, the chief financial officer owned 138,473 shares of the company's stock, valued at $10,337,009.45. This represents a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,108,951 shares of company stock valued at $77,660,938 in the last three months. 26.27% of the stock is currently owned by company insiders.

Tempus AI Stock Up 3.0%

Shares of Tempus AI stock traded up $2.20 on Friday, hitting $75.86. 7,646,161 shares of the company traded hands, compared to its average volume of 11,999,090. The company has a 50-day moving average price of $64.31 and a 200 day moving average price of $59.34. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $91.45. The company has a market cap of $13.18 billion, a PE ratio of -63.75 and a beta of 4.98.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business had revenue of $314.64 million for the quarter, compared to analysts' expectations of $296.84 million. During the same period in the previous year, the company posted ($6.86) EPS. Tempus AI's revenue was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.